Rituximab May Cause Increased Hepatitis C Virus Viremia in Rheumatoid Arthritis Patients Through Declining Exosomal MicroRNA-155.
Tsai-Ling LiaoShie-Liang HsiehYi-Ming ChenHsin-Hua ChenHung-Jen LiuHsiu-Chin LeeDer-Yuan ChenPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
Circulating exo-miR-155 levels were negatively correlated with hepatitis C viral loads and subsequently associated with rituximab-related HCV activity enhancement in RA patients. Exo-miR-155 may become a potential diagnostic biomarker or therapeutic target.
Keyphrases
- hepatitis c virus
- rheumatoid arthritis patients
- cell proliferation
- long non coding rna
- end stage renal disease
- disease activity
- diffuse large b cell lymphoma
- human immunodeficiency virus
- newly diagnosed
- chronic kidney disease
- ejection fraction
- long noncoding rna
- rheumatoid arthritis
- peritoneal dialysis
- systemic lupus erythematosus
- hodgkin lymphoma
- chronic lymphocytic leukemia
- patient reported outcomes
- human health
- hiv infected
- risk assessment
- interstitial lung disease
- climate change
- patient reported
- antiretroviral therapy